PharmaEssentia announced on February 24 that the latest guidelines from the National Comprehensive Cancer Network (NCCN) have designated Ropeginterferon alfa-2b-njft (Ropeg) as a recommended alternative therapy for patients unable to access Peginterferon alfa-2a (Pegasys). This endorsement further solidifies Ropeg’s leadership in the polycythemia vera (PV) treatment landscape and is expected to accelerate its global adoption.
NCCN guidelines serve as a primary reference for hematology-oncology treatments worldwide. Ropeg was already included as a preferred regimen for both high- and low-risk PV. However, in the latest update on February 21, 2025, the NCCN explicitly stated that in the event of a Pegasys shortage, Ropeg should be utilized as the primary alternative. This revision further elevates Ropeg’s status within NCCN’s recommendations, reinforcing its clinical importance in PV management.
In anticipation of increased demand following this designation, PharmaEssentia has proactively expanded production capacity to ensure a stable supply chain and meet market needs efficiently. Beyond production readiness, the company’s medical team is actively collaborating with leading hematology-oncology specialists to enhance treatment accessibility and effectiveness. CEO Dr. Ko-Chung Lin emphasized the urgency of addressing patient concerns regarding Pegasys shortages, mobilizing efforts across the U.S. to provide uninterrupted care.
Pegasys, originally developed and distributed by Roche, was transferred to Austrian pharmaceutical company Pharma& in 2021. However, ongoing production delays have led to widespread shortages across multiple regions, including the EU, UK, and Canada. The U.S. is the last major market affected, with the FDA officially announcing the supply disruption on January 24, 2025, and projecting potential restocking only by May 31, 2026.
Within just four weeks of the FDA announcement, the NCCN swiftly introduced Ropeg as a designated alternative on February 21, 2025. This rapid response aims to alleviate both patient anxiety and clinical challenges arising from the Pegasys supply disruption.
Ropeg is an innovative next-generation long-acting interferon, entirely developed and manufactured by PharmaEssentia. It received FDA approval in 2021 for the treatment of PV, making it the first interferon therapy specifically indicated for all adult PV patients, regardless of prior treatment history. Furthermore, Ropeg remains the only therapy included as a preferred option for both high- and low-risk PV in the NCCN guidelines.
The latest NCCN update reaffirms Ropeg’s position as the sole FDA-approved and NCCN-preferred therapy for comprehensive PV treatment. By explicitly recommending its use in cases of Pegasys unavailability, the guidelines are expected to influence insurance policies and reimbursement frameworks, driving increased adoption among physicians and patients alike. As the demand for innovative PV therapies continues to rise, Ropeg is poised to expand its footprint in the global myeloproliferative neoplasm (MPN) market, setting a new standard for long-acting interferon therapy.
Resource:藥華藥Ropeg獲美國NCCN指定為Pegasys短缺時的替代療法
